PCV15 is NOT currently recommended for routine infant immunization in the United States
The current ACIP guidelines recommend PCV13 or PCV20 for routine infant immunization, not PCV15 1. As of 2024, PCV13 has been removed from the routine immunization schedule notes and replaced with recommendations for PCV15 and PCV20, but the specific guidance prioritizes these newer vaccines differently than you might expect.
Current Guideline Recommendations
For routine infant vaccination:
- The 2024 ACIP immunization schedule has updated pneumococcal recommendations to include PCV15 and PCV20, while removing PCV13 from all sections 1
- The standard infant series consists of a 4-dose schedule at ages 2,4,6, and 12-15 months
- PCV20 appears to be the preferred option when available, based on broader serotype coverage
FDA Approval Status
Important limitation: The FDA label for PCV15 (VAXNEUVANCE) explicitly states it is approved "For use in individuals 18 years of age and older" 2. This is a critical distinction - while the drug label describes pediatric studies, the principal display panel clearly restricts approved use to adults ≥18 years.
Clinical Evidence Context
Despite the FDA age restriction on the label, clinical trials have demonstrated:
- PCV15 shows comparable safety to PCV13 in infants and children 3
- Superior immunogenicity for serotypes 22F and 33F compared to PCV13 3, 4
- The 4-dose infant series (at 2,4,6, and 12-15 months) has been studied and shows appropriate immune responses 2
Why PCV20 Over PCV15
The evidence strongly favors PCV20 for infant programs:
- Modeling studies show PCV15 might actually increase overall invasive pneumococcal disease due to serotype replacement, while PCV20 substantially reduces disease burden 5
- Number needed to vaccinate (NNV) analysis shows PCV20 requires vaccinating only 13 children to prevent one pneumococcal case versus 80 with PCV15 6
- To achieve the same disease reduction as PCV20, over 5 times as many children would need vaccination with PCV15 6
Practical Recommendation
Use PCV20 for routine infant immunization when available. If PCV20 is not accessible, PCV13 remains an acceptable alternative based on its established track record. PCV15 should be reserved for adults ≥18 years per FDA labeling, despite evidence of pediatric immunogenicity.
Common Pitfall
Do not assume "more serotypes than PCV13" automatically means better outcomes - the specific serotypes covered matter significantly. PCV15's two additional serotypes (22F, 33F) provide less population-level benefit than PCV20's seven additional serotypes in preventing overall pneumococcal disease burden.